DE69624355D1 - Verfahren zur arzneistoffabgabe mittels gentherapie - Google Patents

Verfahren zur arzneistoffabgabe mittels gentherapie

Info

Publication number
DE69624355D1
DE69624355D1 DE69624355T DE69624355T DE69624355D1 DE 69624355 D1 DE69624355 D1 DE 69624355D1 DE 69624355 T DE69624355 T DE 69624355T DE 69624355 T DE69624355 T DE 69624355T DE 69624355 D1 DE69624355 D1 DE 69624355D1
Authority
DE
Germany
Prior art keywords
gentherapy
delivery
medicinal products
pharmaceuticals
organs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69624355T
Other languages
English (en)
Other versions
DE69624355T2 (de
Inventor
Karl Tryggvason
Olavi Lukkarinen
Pirkko Heikkilae
Teija Parpala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69624355D1 publication Critical patent/DE69624355D1/de
Publication of DE69624355T2 publication Critical patent/DE69624355T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69624355T 1995-05-16 1996-05-16 Verfahren zur arzneistoffabgabe mittels gentherapie Expired - Fee Related DE69624355T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44218995A 1995-05-16 1995-05-16
PCT/IB1996/000463 WO1996036363A1 (en) 1995-05-16 1996-05-16 Method for pharmaceutical delivery

Publications (2)

Publication Number Publication Date
DE69624355D1 true DE69624355D1 (de) 2002-11-21
DE69624355T2 DE69624355T2 (de) 2003-06-12

Family

ID=23755860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624355T Expired - Fee Related DE69624355T2 (de) 1995-05-16 1996-05-16 Verfahren zur arzneistoffabgabe mittels gentherapie

Country Status (7)

Country Link
US (2) US5871464A (de)
EP (1) EP0831919B1 (de)
AT (1) ATE226094T1 (de)
AU (1) AU5658196A (de)
DE (1) DE69624355T2 (de)
ES (1) ES2187648T3 (de)
WO (1) WO1996036363A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638264B1 (en) * 1995-05-16 2003-10-28 Biostratum Incorporation Perfusion apparatus and methods for pharmaceutical delivery
US6342214B1 (en) * 1995-05-16 2002-01-29 Karl Tryggvason Method for viral vector delivery
US6192138B1 (en) * 1997-05-08 2001-02-20 Kabushiki Kaisha Toshiba Apparatus and method for embedding/unembedding supplemental information
CA2364562A1 (fr) * 1999-04-09 2000-10-19 Aventis Pharma S.A. Composition destinee a la conservation d'adenovirus recombinants infectieux
US20070166292A1 (en) * 1999-04-14 2007-07-19 Breonics, Inc. System for exsanguinous metabolic support of an organ or tissue
US6455257B1 (en) * 2001-02-16 2002-09-24 Richard D. Fuerle Designer diseases
US20040170950A1 (en) * 2002-09-12 2004-09-02 Prien Samuel D. Organ preservation apparatus and methods
US20050153271A1 (en) * 2004-01-13 2005-07-14 Wenrich Marshall S. Organ preservation apparatus and methods
US7722596B2 (en) * 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
WO2006088867A2 (en) * 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
US8152786B2 (en) * 2006-11-07 2012-04-10 Osprey Medical, Inc. Collection catheter and kit
US20080145919A1 (en) * 2006-12-18 2008-06-19 Franklin Thomas D Portable organ and tissue preservation apparatus, kit and methods
US9050400B2 (en) * 2008-08-12 2015-06-09 Osprey Medical, Inc. Remote sensing catheter system and methods
US20100041984A1 (en) * 2008-08-12 2010-02-18 James Edward Shapland Impedance sensing device and catheter system
US9320269B2 (en) 2009-09-25 2016-04-26 John Brassil Organ preservation system
US9295816B2 (en) * 2009-12-09 2016-03-29 Osprey Medical, Inc. Catheter with distal and proximal ports
EP2741804B1 (de) 2011-08-11 2017-04-26 Osprey Medical Inc. Systeme und verfahren zur behandlung der gliedmassen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5338662A (en) * 1992-09-21 1994-08-16 Bio-Preserve Medical Corporation Organ perfusion device
US5336178A (en) * 1992-11-02 1994-08-09 Localmed, Inc. Intravascular catheter with infusion array
US5382229A (en) * 1993-09-21 1995-01-17 Abbott Laboratories Irrigation solution re-circulating system

Also Published As

Publication number Publication date
US5871464A (en) 1999-02-16
AU5658196A (en) 1996-11-29
DE69624355T2 (de) 2003-06-12
ES2187648T3 (es) 2003-06-16
EP0831919B1 (de) 2002-10-16
EP0831919A1 (de) 1998-04-01
ATE226094T1 (de) 2002-11-15
US6689090B1 (en) 2004-02-10
WO1996036363A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
DE69624355D1 (de) Verfahren zur arzneistoffabgabe mittels gentherapie
DE69615561D1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
ATE264671T1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
AU1534699A (en) Osmotic dosage form comprising first and second coats
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
NO20002788D0 (no) Nye forbindelser
DE69431753D1 (de) Verfahren zur bereitung von liposomen mit gaseinschlüssen
ES2114616T5 (es) Acidos dicarboxilicos alifaticos insaturados.
AU6682598A (en) Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
DE69920945D1 (de) Verfahren zur herstellung von arzneistoffpartikeln
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69325393D1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
DE59608150D1 (de) Transdermales therapeutisches system (tts) zur verabreichung von testosteron
BG105275A (en) Tan-1057 derivatives
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATE171620T1 (de) Verwendung von verzweigtkettigen aminosäuren zur herstellung eines arzneimittels zur behandlung von tardiver dyskinesia
DE59708495D1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
ATE253902T1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
DE69804766D1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
WO2001016355A3 (de) In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee